LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

36.88 1.74

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

35.45

Max

37.2

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5M -128M
Pardavimai	6.8M 11M
Pelnas, tenkantis vienai akcijai	-1.23
Pelno marža	-1,191.029
Darbuotojai	594
EBITDA	-18M -139M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+137.11% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-691M 3.7B
Ankstesnė atidarymo kaina	35.14
Ankstesnė uždarymo kaina	36.88

Naujienos nuotaikos

By Acuity

67%

33%

304 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-21 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164 Million

2026-05-21 16:49; UTC

Uždarbis

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

2026-05-21 16:26; UTC

Pagrindinės rinkos jėgos

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

2026-05-21 23:51; UTC

Rinkos pokalbiai

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

2026-05-21 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

2026-05-21 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164M

2026-05-21 21:53; UTC

Uždarbis

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

2026-05-21 21:02; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

2026-05-21 20:55; UTC

Uždarbis

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

2026-05-21 20:30; UTC

Karštos akcijos

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

2026-05-21 20:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-21 20:20; UTC

Rinkos pokalbiai

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Adj EPS 3c >BULL

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Rev $159.9M >BULL

2026-05-21 20:18; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Easing in Early May -- Market Talk

2026-05-21 20:18; UTC

Uždarbis

Webull 1Q Loss/Shr 4c

2026-05-21 19:43; UTC

Rinkos pokalbiai

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-21 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

2026-05-21 18:58; UTC

Uždarbis

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

2026-05-21 18:15; UTC

Rinkos pokalbiai

Gold Higher For Second Consecutive Day -- Market Talk

2026-05-21 17:40; UTC

Rinkos pokalbiai

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

2026-05-21 17:04; UTC

Rinkos pokalbiai

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

2026-05-21 17:01; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

2026-05-21 16:20; UTC

Rinkos pokalbiai

Uždarbis

Stellantis Targets Distant but Constructive -- Market Talk

2026-05-21 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

137.11% į viršų

12 mėnesių prognozė

Vidutinis 86 USD 137.11%

Aukščiausias 97 USD

Žemiausias 67 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

304 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.